| Literature DB >> 28886165 |
Khine Wut Yee Kyaw1, Myo Minn Oo1, Nang Thu Thu Kyaw1, Khaing Hnin Phyo2, Thet Ko Aung2, Theingi Mya3, Nilar Aung4, Htun Nyunt Oo5, Petros Isaakidis6.
Abstract
INTRODUCTION: Loss-to-follow-up (LTFU) throughout the Prevention of Mother-To-Child Transmission (PMTCT) cascade remains one of the major threats to the success of PMTCT programs. In this study, we aimed to determine the mother-to-child transmission rate in a programmatic setting and to determine factors associated with LTFU among enrolled mothers and unfavorable outcomes among HIV-exposed babies which includes being HIV positive, death and LTFU.Entities:
Mesh:
Year: 2017 PMID: 28886165 PMCID: PMC5590939 DOI: 10.1371/journal.pone.0184426
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Programmatic definitions.
| HIV-exposed infant | An infant who is born to an HIV-infected mother until HIVdiagnosis is made. |
| Mother to child transmission of HIV (HIV positive) | an event of an infant who tested positive by DNA/RNA PCR test at 6th week of age or |
| Regular follow up | mother/infant is alive and in care by the date of analysis |
| Lost-to-follow-up (LTFU) | mother/infant missing appointed visit for more than three months |
| Death | mother/infant death, regardless cause of death |
| Transfer out | mother/infant transfer out to other IHC clinic |
Fig 1Cascade of PMTCT program in Central Women Hospital, Mandalay, Myanmar.
HIV; Human Immunodeficiency virus. *babies less than 9 months of age who were under regular follow-up and had not tested for HIV.
Characteristics and factors associated with loss to follow up among HIV-infected mothers enrolled in prevention of mother to child transmission program Mandalay, Myanmar, March 2011- June 2014.
| Maternal characteristics | Total n | LTFU | Rate in 1000 PY | Unadjusted HR | Adjusted HR |
|---|---|---|---|---|---|
| 678 | 101 (15) | 7 (6–9) | |||
| 15–24 | 123 | 20 (16) | 8 (5–13) | 1 | |
| 25–34 | 424 | 55 (13) | 6 (5–8) | 0.84 (0.47–1.48) | |
| ≥ 35 | 131 | 26 (20) | 9 (6–15) | 1.17 (0.6–2.27) | |
| No ART | 60 | 28 (47) | 44 (28–70) | 5.41 (0.65–45.23) | |
| Option A | 136 | 22 (16) | 7 (4–11) | 1.82 (0.98–3.39) | 1.3 (0.46–3.74) |
| Option B | 108 | 24 (22) | 14 (9–22) | ||
| B+/Lifelong | 374 | 27 (7) | 4 (2–5) | 1 | 1 |
| <350 | 221 | 15 (7) | 3 (2–5) | 1 | 1 |
| ≥350 | 192 | 18 (9) | 5 (3–7) | 1.7 (0.82–3.53) | 0.99(0.42–2.34) |
| Missing | 265 | ||||
| I and II | 550 | 89 (16) | 7 (6–10) | ||
| III and IV | 118 | 9 (8) | 3 (1–6) | 1 | |
| Missing | 10 | 3(0.3) | |||
| Alive | 607 | 81 (13) | 6 (5–8) | 1 | |
| Still Birth | 1 | 0 | - | - | |
| Miscarriage | 5 | 1 (20) | 23 (3–165) | 4.25 (0.59–30.77) | |
| Missing | 65 | ||||
| VD | 129 | 26 (20) | 9 (6–14) | 1.6 (0.94–2.72) | 0.71 (0.25–2.05) |
| LSCS | 475 | 55 (43) | 5 (4–7) | 1 | 1 |
| Missing | 74 | 20 (27) | |||
| Home | 37 | 7 (19) | 10 (5–23) | 1.69 (0.73–3.9) | |
| Hospital | 567 | 74 (13) | 6 (5–8) | 1 | |
| Missing | 74 | ||||
| No | 361 | 46 (13) | 6 (5–9) | 1 | |
| Yes | 256 | 51 (20) | 9 (7–13) | 1.5 (0.97–2.33) | |
| Missing | 61 | ||||
| No | 38 | 8 (21) | 11 (5–26) | 1 | |
| Yes | 581 | 89 (15) | 7 (6–9) | 0.79 (0.32–1.95) | |
| Missing | 59 |
¶ LTFU; loss to follow up
* (p value < 0.05)
** (p value < 0.001)
¥PMTCT, prevention of mother to child transmission
# PY, person-years
ƔHR, hazard ratio
λ LSCS, Lower segment caesarean session
δ VD, Normal vaginal delivery
Characteristics and factors associated with unfavorable outcomes (HIV+ diagnosis, death and loss to follow up) among HIV-exposed babies in prevention of mother to child transmission program, Mandalay, Myanmar, March 2011-June 2014.
| Characteristics | Total n (%) | Unfavorable Outcome n (%) | Rate in 1000 PY | Unadjusted HR | Adjusted HR |
|---|---|---|---|---|---|
| 580 | 126 (22) | 13 (11–16) | |||
| Male | 304 | 53 (17) | 11 (8–14) | 0.83 (0.57–1.23) | |
| Female | 257 | 55 (21) | 13 (10–17) | 1 | |
| Missing | 19 | 18 (95) | |||
| ≤2.5 | 11 | 7 (64) | 54 (24–120) | ||
| >2.5 | 540 | 91 (17) | 10 (9–13) | 1 | 1 |
| Missing | 29 | 28 (97) | |||
| Formula Feeding | 489 | 83 (17) | 10 (8–12) | 1 | 1 |
| Breast Feeding | 71 | 32 (45) | 34 (24–48) | 1.95 (0.94–4.10) | |
| Mixed Feeding | 10 | 3 (30) | 24 (8–74) | 2.46 (0.77–7.83) | |
| Missing | 10 | 8 (80) | |||
| AZT¥ | 420 | 64 (15) | 9 (7–12) | 1 | |
| NVP | 61 | 18 (30) | 20 (13–32) | ||
| Missing | 99 | 44 (44) | |||
| No ART | 40 | 22 (55) | 51 (32–82) | ||
| Option A | 120 | 29 (24) | 14 (9–20) | 1.49 (0.93–2.42) | 1 (0.48–2.1) |
| Option B | 97 | 25 (26) | 18 (12–27) | ||
| B+/Lifelong | 323 | 50 (15) | 9 (7–12) | 1 | 1 |
| <350 | 213 | 37 (17) | 9 (7–13) | 1 | |
| ≥350 | 178 | 24 (13) | 8 (5–12) | 0.84 (0.49–1.44) | |
| Missing | 189 | 65 (34) | |||
| ≤12 | 208 | 42 (20) | 12 (9–16) | 1.68 (0.77–3.68) | |
| 12–24 | 112 | 17 (15) | 8 (5–13) | 1.39 (0.66–2.95) | 1.43 (0.60–3.42) |
| >24 | 129 | 14 (11) | 6 (3–10) | 1 | 1 |
| Missing | 131 | 53 (40) | |||
| I and II | 476 | 110 (23) | 13 (11–17) | 1.54 (0.88–2.70) | |
| III and IV | 96 | 14 (15) | 9 (5–15) | 1 | |
| Missing | 8 | 2 (25) | |||
| VD | 124 | 44 (35) | 25 (18–35) | ||
| LSCS | 452 | 80 (18) | 10 (8–13) | 1 | 1 |
| Missing | 4 | 2 (50) | |||
| Home | 36 | 15 (42) | 31 (18–53) | ||
| Hospital | 540 | 109 (20) | 12 (10–15) | 1 | |
| Missing | 4 | 2 (50) | |||
| No | 314 | 67 (21) | 13 (10–16) | 1 | |
| Yes | 217 | 54 (25) | 15 (12–20) | 1.22 (0.84–1.78) | |
| Missing | 49 | 5 (10) | |||
| No | 31 | 8 (26) | 19 (9–38) | 1 | |
| Yes | 501 | 113 (23) | 14 (11–16) | 0.73 (0.35–1.49) | |
| Missing | 48 | 5 (10) |
* (p value < 0.05)
** (p value < 0.001), HIV; Human Immunodeficiency Virus
PY, person-years
HR, hazard ratio
¥AZT, Zidovudine
€NVP, Neviriapine
δ VD, Normal vaginal delivery
λ LSCS, Lower segment caesarean session